Intracoronary Autologous Mesenchymal Stem Cells Implantation in Patients With Ischemic Dilated Cardiomyopathy
A Controlled Open Label Phase II Study Assessing the Efficacy of Intracoronary Autologous Mesenchymal Stem Cells in Patients With Ischemic Dilated Cardiomyopathy
Sponsor: Cytopeutics Sdn. Bhd.
A PHASE2 clinical study on Ischemic Dilated Cardiomyopathy, this trial is ongoing. The trial is conducted by Cytopeutics Sdn. Bhd. and has accumulated 7 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Feb 2019 — Jan 2021 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Feb 2019 [monthly]
Unknown Status PHASE2
▶ Show 2 earlier versions
-
May 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jan 2017 — May 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Jul 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cytopeutics Sdn. Bhd.
- National University of Malaysia
For direct contact, visit the study record on ClinicalTrials.gov .